October 27, 2001
This is an interesting perspective on the perplexing problem of resistance. This group looked at the results of genotypic testing done by Visible Genetics and compared it to actual drugs taken. The results showed that protease inhibitor resistance (46%) was less common than NNRTI resistance (77%) in patients failing initial regimens. However, nucleoside analogue resistance was more common in protease failures (85%) than in NNRTI failures (46%). This is a new finding and may influence the sequence of antiretroviral regimens if confirmed by other trials. Lots of questions remain and further analysis of more patients needs to be done before any firm conclusions can be drawn. However, these can be intriguing results.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|